Indication · Neurology & Neurosurgery
ADHD
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
18
Cleared or approved since 2000
PMA and De Novo
3
Higher-risk or first-of-kind devices
Breakthrough devices
1
Authorized through June 30, 2026
Recruiting device trials
32
174 device trials in all
Breakthrough-designated devices
- Ceribell Delirium Monitor SystemCeribell, Inc. · 2025
Devices
3 devices via De Novo. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- EndeavorRx
Akili Interactive Labs, Inc. · De Novo · Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder · newest 2023 · 2 decisions
2 more devices with a free account
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- AI-assisted Home-based Intervention for ADHD ChildrenPivotal-lookingRecruiting
National Taiwan University HospitalAcademic, hospital or other
NCT07922018 · 120 participants (planned) · Start Aug 1, 2026 · Primary completion Jul 31, 2027
Device: Generative artificial intelligence assisted diary platform home-based intervention · For: ADHD - Attention Deficit Disorder With Hyperactivity; ADHD - Combined Type; ADHD - Inattentive Type
Sites: Hsinchu, Taiwan
173 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on attention deficit hyperactivity disorder across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.